CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

BACKGROUND: Updated evidence was required to compare the efficacy and safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors for patients with hormone receptor-positive and HER2-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hangcheng, Wang, Yan, Han, Yiqun, Wu, Yun, Wang, Jiayu, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449843/
https://www.ncbi.nlm.nih.gov/pubmed/36091147
http://dx.doi.org/10.3389/fonc.2022.956464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449843/
https://www.ncbi.nlm.nih.gov/pubmed/36091147
http://dx.doi.org/10.3389/fonc.2022.956464

Ejemplares similares